StreetAlpha.app
Home › Stocks › IRD

Opus Genetics, Inc. (IRD)

Healthcare
$3.99
▼ −2.21%
LAST CLOSE · NOV 20

Opus Genetics develops gene therapies for inherited retinal diseases that can cause severe vision loss. It last closed at $3.99 on Nov 20, down 2.21% on the day. The next earnings report for IRD is expected around Thu, Feb 18, 2027, after the close. For the quarter ended Sep 2026, IRD reported EPS of -$0.46 on revenue of $1.1M, with revenue down 63.1% from a year ago. Over its last 8 reports the stock moved an average of 3.5% the session after earnings. Over the last 12 months IRD insiders bought $324K of stock on the open market and sold $19.7M, according to SEC Form 4 filings.

AI Auto Pilots
Is IRD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold IRD.

Key Stats

Last 12 months
Results
Revenue
$7.9M
−45.9% vs a year ago
Net income
−$136.7M
−1726.7% margin
EPS (diluted)
−$1.48
Operating margin
−777.7%
−$61.5M operating income
Valuation
Market cap
$385.7M
96.7M shares
P/E
–
No P/E while losing money
Price to sales
48.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$89.0M
At Sep 30
Debt
$35.7M
At Sep 30
Shareholder equity
$38.4M
Shares outstanding
96.7M
At Nov 6
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $589K$589KFY2021FY2022: $39.9M$39.9MFY2022FY2023: $19.0M$19.0MFY2023FY2024: $11.0M$11.0MFY2024FY2025: $14.2M$14.2MFY2025

From IRD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Next report
Feb 18
Estimated date · After the close
Reported EPS
-$0.46
Quarter ended Sep 2026
Year ago EPS
-$0.25
Same quarter last year
Revenue
$1.1M
−63.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$1.27Dec '24Mar 2025: -$0.24Mar '25Jun 2025: -$0.12Jun '25Sep 2025: -$0.25Sep '25Dec 2025: -$0.21Dec '25Mar 2026: -$0.75Mar '26Jun 2026: -$0.14Jun '26Sep 2026: -$0.46Sep '26Latest -$0.46
Revenue by quarter
Dec 2024: $4.3MDec '24Mar 2025: $4.4MMar '25Jun 2025: $2.9MJun '25Sep 2025: $3.1MSep '25Dec 2025: $3.9MDec '25Mar 2026: $2.2MMar '26Jun 2026: $755,000Jun '26Sep 2026: $1.1MSep '26Latest $1.1M
How IRD moved after its last 8 reports
Average move the session after a report ±3.5%
Nov 10, 2026Time not announced+0.7%
Aug 6, 2026Time not announced−1.6%
May 12, 2026Time not announced+1.2%
Feb 19, 2026After the close−5.0%
Nov 12, 2025Time not announced−2.5%
Aug 13, 2025After the close+7.3%
May 15, 2025Time not announced0.0%
Mar 20, 2025After the close+9.6%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on IRDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on IRD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on IRD

Technical Analysis

IRD · as of the Nov 20 close · updated each morning
Turning down

The stock sits between its 20 and 50 day averages. It is 8% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the Pivot at $3.98, and the nearest resistance the Pivot R1 at $4.06.

Short trendBearish
Long trendNeutral
MomentumImproving
StretchNormal
VolatilityNormal, 7.2%/day
Key levels
$7.0752 week high+77.2%
$4.3550 day average+9.0%
$4.30200 day average+7.8%
$4.21Swing high (Oct 21)+5.5%
$4.12100 day average+3.3%
$4.06Pivot R1+1.8%
$3.99Last close
$3.98Pivot−0.3%
$3.9420 day average−1.3%
$3.91Pivot S1−2.0%
$3.90Swing low (May 27)−2.3%
$1.8652 week low−53.4%
Indicators
RSI (14)47.76Middle of its rangeNeutral
MACD-0.03Above its signal lineBullish
Stochastic43.0Middle of its rangeNeutral
ADX (14)8.7No clear trend
Williams %R-68.0Oversold below −80, overbought above −20Neutral
CCI (20)15.9Oversold below −100, overbought above 100Neutral
Rate of change−4.5%Change over 10 sessionsBearish
ATR (14)$0.29Typical daily range, 7.2% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for IRD

What happened before

See how IRD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow IRD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How IRD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for IRDHow many large options trades hit IRD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

IRD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲77 buying vs 39 selling
  • ▲Held by funds +17.9 pts
  • ▲Funds holding +11
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding114103+10.7%
In funds' top 10110.0%
Held by funds80.5%62.7%+17.9 pts
New / increased26 / 5139 / 31+10.0%
Reduced / sold out23 / 1612 / 16+39.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IRD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

IRD Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$324K1 buy · 1 insider
Sold$19.7M23 sales · 7 insiders
2025-12 bought $324K2025-12 sold $8.6M2026-03 sold $181K2026-04 sold $202K2026-05 sold $7.4M2026-07 sold $87K2026-09 sold $2.9M2026-10 sold $218K2026-11 sold $110KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 3George MagrathCEOSale28,258$3.90$110K
Oct 23George MagrathCEOSale9,591$3.58$34K
Oct 23Robert E. GagnonCFOSale plan14,000$3.55$50K
Oct 23Benjamin R YerxaPresidentSale33,189$3.54$117K
Oct 23Joseph K SchachleCOOSale4,767$3.56$17K
Sep 30Foundation Fighting Blindness Retinal Degeneration FundDirectorSale556,000$4.96$2.8M
Every insider buy and sale for IRD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See IRD insider trades →

From SEC Form 4 filings by IRD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IRD is in one of them and how their past IRD trades turned out.

IRD in the AI portfolios
Loading…

IRD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IRD in an article yet. Here's the latest on the wider market.

IRD in the news

About Opus Genetics

Opus Genetics is a biopharmaceutical company based in Durham, North Carolina. It is developing gene therapies meant to restore vision and prevent blindness in people with inherited retinal diseases, including Leber congenital amaurosis, bestrophinopathy and retinitis pigmentosa. The company is also developing a prescription eye solution for other ophthalmic conditions, and its target patients are people facing severe, often early-onset, eye disorders.

Headquarters
Durham, NC